Palisade Bio (PALI) Accumulated Expenses (2010 - 2026)
Palisade Bio (PALI) reported Accumulated Expenses of $122000.0 for Q1 2026, up 3.39% year-over-year from $118000.0 in Q1 2025, and down 90.6% on a QoQ basis from $1.3 million in Q4 2025.
Palisade Bio (PALI) has 16 years of Accumulated Expenses data on file, last reported at $122000.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 3.39% year-over-year to $122000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122000.0 (up 3.39% YoY) and the FY2025 annual result came in at $1.3 million, up 4.68% from the prior year.
- Accumulated Expenses eased to $122000.0 in Q1 2026 per PALI's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.7 million in Q1 2024 and bottomed at $118000.0 in Q1 2025.
- The 5-year median for Accumulated Expenses is $574000.0 (2022), against an average of $662941.2.
- The widest annual swing landed in 2024, when Accumulated Expenses soared 774.35%; it then slumped 92.93% in 2025.
- Tracing PALI's Accumulated Expenses over 5 years: stood at $574000.0 in 2022, then jumped by 44.77% to $831000.0 in 2023, then soared by 49.22% to $1.2 million in 2024, then grew by 4.68% to $1.3 million in 2025, then tumbled by 90.6% to $122000.0 in 2026.
- Per Business Quant, the three latest PALI Accumulated Expenses figures stand at $122000.0 (Q1 2026), $1.3 million (Q4 2025), and $621000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122,000.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 449,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 831,000.00 |
| Sep 30, 2023 | 529,000.00 |
| Jun 30, 2023 | 291,000.00 |
| Mar 31, 2023 | 191,000.00 |
| Dec 31, 2022 | 574,000.00 |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 1.03 Mn |
| Mar 31, 2022 | 580,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Sep 30, 2021 | 722,000.00 |
| Jun 30, 2021 | 164,000.00 |
| Mar 31, 2021 | 274,261.00 |
| Dec 31, 2020 | 2.74 Mn |
| Sep 30, 2020 | 98,750.00 |
| Jun 30, 2020 | 98,750.00 |
| Mar 31, 2020 | 98,750.00 |
| Dec 31, 2019 | 135,686.00 |
| Dec 31, 2017 | 418,625.00 |
| Dec 31, 2016 | 852,963.00 |
| Mar 31, 2016 | 287,046.00 |
| Dec 31, 2015 | 161,362.00 |
| Sep 30, 2015 | 767,989.00 |
| Jun 30, 2015 | 490,749.00 |
| Mar 31, 2015 | 225,321.00 |
| Dec 31, 2014 | 646,960.00 |
| Dec 31, 2013 | 465,868.00 |
| Sep 30, 2013 | 462,882.00 |
| Jun 30, 2013 | 313,088.00 |
| Mar 31, 2013 | 410,452.00 |
| Dec 31, 2012 | 465,865.00 |
| Sep 30, 2012 | 479,368.00 |
| Jun 30, 2012 | 319,578.00 |
| Mar 31, 2012 | 657,466.00 |
| Dec 31, 2011 | 582,675.00 |
| Sep 30, 2011 | 539,548.00 |
| Jun 30, 2011 | 381,322.00 |
| Dec 31, 2010 | 453,240.00 |